Figure 3.

Multimodal approaches targeting oncogenic EGFR in NSCLC. Multiple approaches such as monoclonal antibodies (that target the extracellular ligand-binding domain), orthosteric and allosteric inhibitors, and small peptides designed to block the oncogenic kinase of the EGF receptor, are currently being evaluated in NSCLC therapy. The EGFR crystal structure was drawn using the PyMOL Molecular Graphics System based on protein Data Bank accession codes 3NJP for extracellular and transmembarne domain interfaces, 2M0B for transmembrane domain, and 3GOP for juxtamembrane and kinase domains.